pharma · Lymphoma · Gastrointestinal Stromal Tumors · COGT
Cogent Biosciences
Cogent Biosciences clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451, US
- Founded
- 2014
- Employees
- 283
- Programs
- 13
- Drugs
- 8
- Patents
- 10
Cogent Biosciences projects
6 ClinicalTrials.gov programs sponsored by Cogent Biosciences.
Cogent Biosciences has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Bezuclastinib Tablets (Formulation A)
Cogent Biosciences
SSM
1 trial -
Bezuclastinib in combination with sunitinib
Cogent Biosciences
Gastrointestinal Stromal Tumors
1 trial -
CGT4859
Cogent Biosciences
Intrahepatic Cholangiocarcinoma (Icc)
1 trial -
CGT9486
Cogent Biosciences
Gastrointestinal Stromal Tumors
1 trial -
CGT9486, CGT9486
Cogent Biosciences
Advanced Systemic Mastocytosis
1 trial -
bezuclastinib
Cogent Biosciences
Advanced Systemic Mastocytosis (AdvSM)
1 trial
Frequently asked questions
How many clinical projects does Cogent Biosciences have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.